A real ‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab

CONCLUSION: Our study found potential new and unexpected AEs signals for daratumumab, suggesting prospective clinical studies are needed to confirm these results and illustrate their relationship.PMID:38600747 | DOI:10.1080/14740338.2024.2328321
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Source Type: research